India’s drug regulatory body, CDSCO, has banned 35 fixed-dose combination drugs, including painkillers and anti-diabetics, due to safety concerns. These combinations were manufactured and sold without proper evaluation, posing risks to public health. The decision aims to prevent adverse reactions and ensure the scientific validation of drug combinations, urging caution among doctors and patients.